Clinical Report: Amendment: Enhancing the Application of VExUS Score
Background
The VExUS score has gained attention as a non-invasive tool for assessing venous congestion, which is critical in managing fluid overload in patients. Understanding its utility and limitations is essential for optimizing patient care in perioperative and critical care environments.
Data Highlights
No numerical or trial data provided in the source material.
Key Findings
The author name was corrected from Guinot Pierre-Grégoire to Pierre-Grégoire Guinot.
The VExUS score is an emerging tool for evaluating venous congestion in critical care settings.
There is ongoing research to refine the understanding of what VExUS quantifies.
Guidelines suggest using critical care ultrasonography, including VExUS, for managing septic and cardiogenic shock.
Consensus recommendations for VExUS teaching and competency assessment are being developed.
Clinical Implications
The correction of the author's name ensures proper attribution in the literature.
Conclusion
Accurate author attribution is crucial for scholarly communication.
Dana-Farber Cancer Institute's Dr. Julia Rotow reported on a study looking at silevertinib, with data showing it may offer a new first-line option for hard-to-treat EGFR non-small cell lung cancer variants, with encouraging brain activity and manageable side effects.
Brazilian pediatric intensive care unit study found underweight status was associated with respiratory complications, longer hospitalization, and mortality among critically ill patients with COVID-19.
